Alexander E. Perl, MD | Authors


Highlighting Latest Additions to the Treatment Landscape for AML

May 08, 2019

Alexander E. Perl, MD, discusses the latest advancements in the treatment landscape for patients with acute myeloid leukemia. These advances are driven by 2 factors: a better understanding of the biology of the disease and improving therapeutics to meet that understanding.

Dr. Perl on Survival Improvement With Gilteritinib in FLT3+ AML

April 12, 2019

Alexander E. Perl, MD, discusses results from the phase III ADMIRAL trial, which demonstrated a significant improvement in overall survival in patients with FLT3-mutated acute myeloid leukemia treated with the FLT3 inhibitor gilteritinib.